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Edited by I. WilsonAbstractHepatitis C virus (HCV) infection is a major cause of liver disease and hepatocellular carcinoma. Glycan
shielding has been proposed to be amechanism by which HCVmasks broadly neutralizing epitopes on its viral
glycoproteins. However, the role of altered glycosylation in HCV resistance to broadly neutralizing antibodies is
not fully understood. Here, we have generated potent HCV neutralizing antibodies hu5B3.v3 and
MRCT10.v362 that, similar to the previously described AP33 and HCV1, bind to a highly conserved linear
epitope on E2. We utilize a combination of in vitro resistance selections using the cell culture infectious HCV
and structural analyses to identify mechanisms of HCV resistance to hu5B3.v3 and MRCT10.v362. Ultra deep
sequencing from in vitro HCV resistance selection studies identified resistance mutations at asparagine N417
(N417S, N417T and N417G) as early as 5 days post treatment. Comparison of the glycosylation status of
soluble versions of the E2 glycoprotein containing the respective resistancemutations revealed a glycosylation
shift from N417 to N415 in the N417S and N417T E2 proteins. The N417G E2 variant was glycosylated neither
at residue 415 nor at residue 417 and remained sensitive to MRCT10.v362. Structural analyses of the E2
epitope bound to hu5B3.v3 Fab and MRCT10.v362 Fab using X-ray crystallography confirmed that residue
N415 is buried within the antibody–peptide interface. Thus, in addition to previously described mutations at
N415 that abrogate the β-hairpin structure of this E2 linear epitope, we identify a second escape mechanism,
termed glycan shifting, that decreases the efficacy of broadly neutralizing HCV antibodies.
© 2013 Elsevier Ltd. Open access under CC BY-NC-ND license.Introduction
Hepatitis C virus (HCV), a member of the
Flaviviridae family of viruses, is a major cause of
chronic hepatitis and hepatocellular carcinoma.1,2
The HCV genome is a positive-strand, ~9.6-kb RNA
molecule consisting of a single open reading frame0022-2836 © 2013 Elsevier Ltd. Open access under CC BY-NC-ND liceflanked by 5′ and 3′ untranslated regions (UTRs).
The HCV 5′UTR contains a highly structured internal
ribosome entry site2–6 while the 3′ UTR is essential
for replication.7–9 The HCV open reading frame
encodes a single polyprotein of ~3000 amino acids
in length and is posttranslationally processed to
produce at least 10 different proteins: core, envelopeJ. Mol. Biol. (2013) 425, 1899–1914nse.
1900 Glycan Shifting in HCV Antibody Resistanceproteins E1 and E2, p7 and non-structural proteins
NS2, NS3, NS4A, NS4B, NS5A and NS5B.1,10,11
HCV entry into hepatocytes occurs through the
coordinated interactions between the HCV E1–E2
heterodimer and at least four essential cellular
factors: CD81,12 scavenger receptor B type I,13
occludin14,15 and claudin 1 (CLDN1).16 In particular,
the HCV E2 glycoprotein binds CD81 and scavenger
receptor B type I, and anti-HCV E2 neutralizing
antibodies, especially ones that bind to a highly
conserved epitope on E2 (E2412–423), are broadly
neutralizing across multiple HCV genotypes.17–22
The extracellular domains of both E1 and E2 are
heavily glycosylated, and some glycans are critical
for viral infectivity in vitro.23 HCV resistance to
neutralizing antibodies can arise from the high
mutational rate of the HCV polymerase (~10−4 per
nucleotide per generation), shielding of the E1–E2
glycoproteins by virion-associated lipoproteins or the
presence of non-neutralizing antibodies that prevent
binding of neutralizing antibodies.24 Recent studies
have revealed the importance of glycosylated aspar-
agine (Asn) residues in E2 in the masking of epitopes
recognized by broadly neutralizing antibodies.23,25,26
Multiple glycans on E2, including those on N417 and
N423 (termed E2N1 and E2N2 in the literature),
decrease sensitivity of infectious cell culture HCV
(HCVcc) and HCV pseudoparticles (HCVpp) to
neutralization by patient antisera and modulate
binding of a soluble form of CD81, suggesting that
glycans play an important role in masking the CD81
binding epitope on E2.25–27 However, many of these
mutational analyses have involved substitutions with
alanine25 or glutamine23 residues and it is unclear
whether viruses bearing these changes are compe-
tent for viral entry. Although Dhillon et al. have
demonstrated that virus isolates containing muta-
tions at N415 and N417 confer resistance to the
murine monoclonal antibody AP33,28 the mecha-
nisms of resistance were not clear.
Recently, using crystal structures of two other
E2412–423-specific neutralizing antibodies, HCV1
and AP33, complexed with its peptide epitope,
Kong et al. and Potter et al. have demonstrated
that mutations at N415 can result in loss of HCVTable 1. HCVpp neutralization of affinity-matured E2412–423-sp
Antibodies GT1a (H77)
AP33 0.34 ± 0.013
MRCT10.v362 0.07 ± 0.02
mu5B3 0.52 ± 0.14
hu5B3.v3 0.73 ± 0.62
HCV1 4.81 ± 2.28
Anti-CD81 0.35 ± 0.085
Anti-CLDN1 7.38 ± 0.75
All values represent averages ± SEM and are representative of at l
Average EC90 values for mu5B3 and hu5B3.v3 were generated fromneutralization as this residue is within the antibody–
peptide interface.29–31 In this report, we identify
N417S and N417T HCVcc variants that are resistant
to two broadly neutralizing affinity-matured anti-
bodies, MRCT10.v362 and hu5B3.v3, and conclude
that a glycosylation shift from residue N417 to N415
causes this resistance. Furthermore, in spite of the
emergence of robust resistance of the N417S
HCVcc variant, combination with an approved HCV
direct acting antiviral (DAA) resulted in significant
suppression of resistance to both HCV DAA and
MRCT10.v362. Cumulatively, our data demonstrate
that shifts in the glycan attachment site within the
CD81 binding epitope on E2 play a critical role in
conferring resistance to neutralizing antibodies and
that combining viral entry inhibitors with HCV
antivirals with an orthogonal mechanism of action
can enhance the antiviral effect and suppress
emergence of these resistant variants.Results
Rapid and robust HCV genotype-specific
resistance develops to E2412–423-specific
neutralizing antibodies in vitro
The humanization and affinity maturation of the
murine antibodies AP33 and mu5B3 to generate
MRCT10.v362 and hu5B3.v3, respectively, are
described in detail in Supplemental Materials.
MRCT10.v362 and hu5B3.v3 had ~2-fold increased
binding affinity to soluble versions of E2 (sE2661)
from both genotype 1a and genotype 1b relative to
the parental antibodies as shown by surface
plasmon resonance (SPR) analysis (Table S2).
The affinity improvements resulted primarily from a
decreased off-rate. Kinetics of binding were slower
for hu5B3.v3 compared to MRCT10.v362. In com-
parison, both affinity-matured variants hu5B3.v3 and
MRCT10.v362 had significantly improved in vitro
neutralization potencies compared to their parental
murine antibodies, mu5B3 and AP33, against both
HCVpp (Table 1) and wild-type genotype 2a Jc1ecific antibodies
HCVpp neutralization (EC90, μg/mL)
GT1b (Con1) GT2a (J6CF)
6.86 ± 1.27 7.94 ± 2.45
2 ± 0.11 1.76 ± 0.4
44.7 ± 15.73 107.7 ± 22.32
9.22 ± 4.3 17.48 ± 9.46
93.4 ± 35.29 72.3 ± 7.79
0.286 ± 0.22 0.15 ± 0.05
6.45 ± 2.58 3.84 ± 1.74
east two independent experiments each performed in triplicate.
at four independent experiments.
Table 2. Effect of mutations identified in Jc1 E2412–423 on Jc1 HCVcc sensitivity to HCV antibodies and antivirals
EC90 of Jc1 HCVcc variants to HCV antivirals (μg/mL)
N417 (WT) N417S N417T N417G N415D
AP33 4.6 ± 0.95a N100a N100 9.7 ± 5.1 N100
MRCT10.v362 0.58 ± 0.27a N100a N100 1.23 ± 0.26 N100
mu5B3 5.1 ± 2.9 N100 N100 24.5 ± 12.9 N100
hu5B3.v3 0.66 ± 0.32 N100 N100 7.1 ± 0.98 N100
HCV1 2.3 ± 0.36 N100 N100 42 ± 3.8 N100
Anti-CD81 0.089 ± 0.06 0.023 ± 0.003 0.032 ± 0.005 0.032 ± 0.018 0.032 ± 0.006
Anti-CLDN1 0.18 ± 0.003a 0.263 ± 0.1a 0.174 ± 0.032a 0.22 ± 0.13a 0.54 ± 0.15a
All values represent averages ± SEM and are representative of at least two independent experiments each performed in triplicate.
a Values are determined from three independent experiments.
1901Glycan Shifting in HCV Antibody ResistanceHCVcc (Table 2). Subsequent binding studies using
the E2412–423 peptide demonstrated that mu5B3
bound to a similar overlapping peptide as AP33 (data
not shown).
Since hu5B3.v3 and MRCT10.v362 bound a
similar epitope on E2, we wanted to determine
whether mutations that conferred AP33 resistance
in Jc1 (chimeric genotype 2a) and Con1/C3-neo
(chimeric genotype 1b) HCVcc would also lead to
resistance against hu5B3.v3. To identify mutations
conferring resistance to AP33, we selected for
resistant isolates by gradually increasing the
antibody concentration in two ways. The first
involved sequential passaging of supernatants
from infected cells onto uninfected cells to identify
dominant resistant isolates (Fig. 1a). The second
involves continuous passaging of infected cells in
order to allow for the assembly and release of
variants that may be attenuated in growth and
spread (Fig. 1a). Incubation of genotype 2a Jc1
HCVcc with increasing concentrations of AP33
resulted in an initial ~10-fold decrease in HCV
RNA replication followed by a rapid rebound in
HCV RNA replication as early as 10 days post
infection (Fig. 1b). Within 2 weeks, the levels of
HCV RNA replication were similar to that of
cultures not treated with antibody (Fig. 1b). In
comparison, no resistant virus could be detected by
passaging supernatants from genotype 1b chimeric
Con1/C3 HCVcc-infected Huh7.5 cells (Fig. 1b).
Culturing in the presence of a control antibody did
not lead to a decrease in HCV RNA replication and
spread (data not shown).
Bulk sequencing and single genome sequencing
using primers surrounding the E2412–423 epitope
revealed single point mutations at residues 417
(N417S) and 415 (N415D) in the continuous Jc1
HCVcc supernatant and cell passaging experiments,
respectively. While no dominant mutations were
detected in the Con1/C3 supernatant passage
experiment, the N415D mutation was detected in
continuously passaged Con1/C3 HCVcc-infected
cells by single genome sequencing (data not
shown). To further determine if additional sub-
dominant resistance mutations exist and to under-stand the kinetics of the emergence of these
mutations, we performed 454 ultra deep sequencing
analysis of Jc1 HCVcc-infected cells at various times
post infection and determined the frequency of
amino acids at positions 415 and 417. Between
16,000 and 25,000 reads per treatment per time
point were analyzed. In the absence of any selecting
antibody, the wild-type N415 (data not shown) and
N417 (Fig. 1c) sequences were the dominant
species (N94%) in the culture at all time points
tested. No enrichment of N415 variants was
detected in the supernatant passed cultures (data
not shown). However, compared to untreated cells,
incubation with AP33 resulted in a 39-fold (8.5%
versus 0.2%) and 138-fold (23.4% versus 0.17%)
enrichment of Jc1 HCVcc genomes containing
N417S and N417T mutations, respectively, as
early as 5 days post selection (Fig. 1c). By 15 days
post infection, the N417S HCVcc variant had
become the dominant species (Fig. 1c). N417G
Jc1 HCVcc variants were detected but not enriched
in antibody-treated infections.
N417S and N417T Jc1 HCVcc are resistant to
hu5B3.V3 and MRCT10.v362 neutralization
In order to determine whether N417S, N417T,
N417G and N415D mutations conferred resistance
to E2412–423-specific neutralizing antibodies, we
independently introduced each of these mutations
into Jc1 HCVcc and tested the ability of various
antibodies to inhibit entry and infection. AP33 and
HCV1 antibodies were used as controls. As
expected, the N417S, N417T and N415D HCVcc
were completely resistant to inhibition by all
E2412–423-specific neutralizing antibodies AP33,
MRCT10.v362, mu5B3, hu5B3.v3 and HCV1
(Table 2). In comparison, all HCVcc variants were
equivalently sensitive to anti-CD81 and anti-CLDN1
neutralizing antibodies (Table 2). Interestingly, while
both wild-type and N417G HCVcc remained equiv-
alently sensitive to AP33 and MRCT10.v362, the
N417G variant was more resistant to mu5B3,
hu5B3.v3 and HCV1 (~5-fold, 11-fold and 18-fold,
respectively). The lack of enrichment of the N417T
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Fig. 1. Identification and characterization of mutant Jc1 and Con1/C3-neo HCVcc resistant to E2412–423-specific
neutralizing antibody (AP33). (a) Supernatants and cells from Jc1 (squares) and Con1/C3-neo (circles) HCVcc-infected
Huh7.5 cells were sequentially cultured in the absence (filled symbols) or presence (open symbols) of increasing
concentrations of AP33, and (b) HCV RNA replication was measured at various times post infection. These are
representative data from three independent experiments. (c) 454 Ultra deep sequencing analysis of N417 amino acid
variations over time demonstrating an enrichment of the N417S mutant HCVcc when cultured in the presence of antibody
(WT, black; N417S, red; N417T, orange; N417G, green). (d) The effect of the mutations on HCVcc infectivity was
determined by introducing them in Jc1 HCVcc and monitoring growth in culture over 9 days. (e and f) The effect of the
identified mutations on infectivity of HCVpp was determined. HCVpp stocks were generated and normalized using p24
levels in the supernatants (e) followed by infecting Huh7.5 cells to measure infectivity (f). No pseudoparticles were
generated in the absence of E1E2-expressing plasmid as determined by p24 levels. In vitro growth and infectivity studies
are representative data from at least two independent experiments. p values: *p b 0.05, **p b 0.01 and ***p b 0.001.
1902 Glycan Shifting in HCV Antibody ResistanceHCVcc in the in vitro resistance selection is likely due
to its ≥10-fold decreased infectivity in vitro (Fig. 1d).
Since no resistant mutations were detected using
the genotype 1b chimeric virus Con1/C3-neo, we
wanted to determine whether the resistance muta-tions, when present in genotype 1 HCV, resulted in
decreased infectivity. The N415 and N417 mutations
were introduced into H77, Con1 and J6CF E1E2-
expressing plasmids by site-directed mutagenesis
and HCVpp stocks were generated. As a control, we
1903Glycan Shifting in HCV Antibody Resistanceintroduced the N415Y mutation into genotype 1a E2
that has been previously demonstrated to confer
resistance to AP33.32 Equivalent levels of each
HCVpp variant were generated as measured by p24
levels in the supernatant after co-transfection with
the lentiviral vectors. No p24 was detected in the
absence of co-transfection of E1E2-expressing
plasmid (Fig. 1e). While N417S HCVpp infectivity
was only modestly decreased (~2.6-fold) compared
to that of wild-type HCVpp from genotype 2a J6CF
(Fig. 1f), introduction of N417S resulted in signifi-
cantly decreased entry of genotypes 1b and 1a
HCVpp (~14-fold and ~22-fold, respectively). In(a)
0.1 1 10 10
0
10
00
N423A
I422A
H421A
W420A
S419A
G418A
N417A
T416A
N415A
I414A
L413A
Q412A
hu5B3.v3
Log KD Ratio 
(mutant/WT peptide)
M
ut
an
t E
24
12
-4
23
 
Pe
pt
id
es
(c)
MRCT10.v362
*
*
*
-2000
0
2000
4000
6000
8000
1 104
0 100 200 300 400 500 600 700
R
es
on
an
ce
 
Un
its
Time (sec)
KD=70  nM
Fig. 2. Binding of hu5B3.v3 and MRCT10.v362 to wild-typ
peptides. (a) Ratio of dissociation constants (KD) for MRCT10.
peptides relative to WT peptide QLINTNGSWHINGSGK-biotin
detected with mutant peptides. (b) Binding of various E2412–423
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peptide with faster off-rate compared to WT. Dissociation conscomparison, the infection of N417T and N415D
HCVpp were significantly decreased in all HCVpp
genotypes tested (Fig. 1f). The N415Y genotype 1a
HCVpp was modestly attenuated compared to wild-
type H77 HCVpp, similar to what has been previ-
ously described.32
Loss of hu5B3.V3 and MRCT10.v362 binding to
N417S and N417T E2 glycoproteins expressed in
mammalian cells
We compared binding of hu5B3.V3 and MRCT10.
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N4
17
(WT
)
N4
17
G
N4
17
S
N4
17
T
N4
15
D
No
 E2
0
1
2
3
ELISA Lysate Coat
(d)
mu5B3
hu5B3.v3
HCV1
AP33
MRCT10.v362
KD =270 nM
-1000
0
1000
2000
3000
4000
5000
6000
0 100 200 300 400 500 600 700
R
es
on
an
ce
 
Un
its
Time (sec)
O
D 4
50
e and mutant soluble E2 proteins (sE2661) and E2
412–423
v362 (red) and hu5B3.v3 (black) binding to alanine mutant
(E2412–423-biotin) are graphed. Asterisks denote no binding
-specific neutralizing antibodies to lysates of untransfected
6CF) HCV E1E2-expressing plasmids containing various
m three independent experiments. (c and d) MRCT10 Fab
binding of MRCT10 Fab to WT (c) or N417S (d) E2412–423
down to 15.6 nM. MRCT10 Fab binds to N417SE2412–423
tants (KD) are listed in the graphs.
1904 Glycan Shifting in HCV Antibody Resistanceexpressed in transfected cells. Binding of Fab
fragments to chemically synthesized peptides (non-
glycosylated) was measured by SPR or bio-layer
interferometry. Both MRCT10.v362 and hu5B3.v3
showed measurable binding affinity to the E2412–423
peptide epitope with KD values of 30 nM and 12 nM,
respectively (data not shown). Binding studies using
alanine mutations of the peptide demonstrated some
similarities for the two antibodies (Fig. 2a).While both
MRCT10.v362 and hu5B3.v3 did not bind W420A
mutant peptide, they bound both wild-type and
N417A mutant peptides equivalently (Fig. 2a). In
comparison, while mutants L413A and G418A
exhibited ~64-fold and ~174-fold decreases in
binding affinity for hu5B3.v3, respectively, they only
affected MRCT10.v362 binding by ~8-fold and ~2-
fold, respectively (Fig. 2a). In addition, while binding
of MRCT10.v362 to N415A only decreased by 2.8-
fold, binding of hu5B3.v3 was completely lost
(Fig. 2a). These data suggest that both MRCT10.
v362 and hu5B3.v3 bind similar epitopes through
different interactions.
Since the region surrounding the E2412–423
epitope is highly glycosylated on virion-associated
E2, we wanted to determine whether these
posttranslational modifications would affect binding
of hu5B3.v3 or MRCT10.v362. In order to deter-
mine if hu5B3.v3 and MRCT10.v362 bound recom-
binant E2 containing the N417S or N417T
mutations, we tested antibody binding to a soluble
E2 glycoprotein variant (sE2661) or E1E2 ex-
pressed in cells using SPR and ELISA, respec-
tively. SPR measurements indicated that affinity of
hu5B3.v3 and MRCT10.v362 for N417S and
N417T sE2661 was reduced at least 100-fold
(KD N 500 nM) whereas binding of N417G sE2661
was decreased only 3-fold (data not shown).
Furthermore, hu5B3.v3 and MRCT10.v362 binding
to E1E2-expressing 293T cell lysates demonstrat-Table 3.H-bonds within the E2 peptide (Å) for MRCT1.v362 and
peptide structures
Atom 1 Atom 2 5B3
v362
chain Z
v362
chain Y
Q412 O N423 N 3.2 —a —
I414 N H421 O 2.9 2.9 2.9
I414 O H241 N 3.0 2.9 2.8
N415 Oδ1 G418 N 2.9 3.1 3.1
N415 Oδ1 S419 N 3.1 — —
T416 N S419 O — 3.0 3.0
T416 O S419 N — 3.1 3.1
T416 Oγ1 H421 Nε2 — 2.8 2.7
N417 N N417 Oδ1 2.7 — —
N417 Oδ1 S419 Oγ 3.0 — —
S419 Oγ H421 Nε2 — — —
I422 O N423 Nδ2 — 2.9 —
“5B3” is hu5B3.v3, and “v362” is MRCT10.v362. Abbreviation: PDB, P
a No H-bond.
b One of the atoms is not present in coordinates.ed no detectable binding to N417S, N417T or N415D
with any of the E2412–423-specific antibodies
(Fig. 2b). Interestingly, MRCT10 Fab still bound the
N417S peptide, although with ~3.9-fold less affinity
compared to the wild-type peptide (Fig. 2c and d).
These data are consistent with the hypothesis that
posttranslational modifications on the native N417S
or N417T E2 protein in the E2412–423 epitope may
prevent antibody binding.
N415 is glycosylated in the N417S and N417T
mutant E2 proteins
Identifying glycosylated Asn residues on E2
derived from intact HCVcc particles is technically
challenging. Since sE2661 has been demonstrated to
retain many aspects of the E2 glycoprotein including
CD81 binding, we determined the glycosylation
status of Asn residues within the E2412–423 epitope
in sE2661 proteins secreted by Huh7.5 cells, as these
are the same cells used for HCVcc infection and
virus production in vitro. Huh7.5 cells were trans-
fected with plasmids expressing recombinant J6CF
sE2661 variants containing N417 (WT), S417, T417
or G417 mutations. The sE2661 proteins were
purified and asparagine glycosylation state within
the E2412–423 epitope was characterized by mass
spectrometry (MS), as performed previously.33
Concordant with previously published results,33
wild-type sE2661 was glycosylated at both N417
and N423 (Fig. S2a). Not surprisingly, while both
N417S and N417T sE2661 were glycosylated at
N415 and N423 (Fig. S2b and c), the N417G sE2661
was only glycosylated at N423 (Fig. S2d). Since
N417G Jc1 HCVcc was not attenuated in vitro and
both wild-type and N417G HCVcc remained equiv-
alently sensitive to MRCT10.v362 neutralization, our
data suggest that the glycosylation shift from residue
417 to residue N415 may be important for generatinghu5B3.v3 compared to other E2412–423-specific antibody–
HCV1
PDB 4GDV
HCV1
PDB 4GDY
AP33
PDB 4GAG
AP33
PDB 4GAJ
2.9 2.9 b —
2.8 2.7 2.8 3.0
2.9 2.9 2.9 2.9
2.8 3.0 3.1 2.9
— — — —
2.9 2.9 2.9 3.1
3.1 2.9 3.1 2.8
— 2.9 — 2.5
— — — —
— — — —
— — 2.8 —
— — — b
rotein Data Bank.
1905Glycan Shifting in HCV Antibody Resistancerobust resistance to neutralizing antibodies that bind
the E2412–423 epitope.
Structural analyses of MRCT10.v362 and hu5B3.v3
complexed with the E2412–423-GSGK-biotin peptide
reveal that a glycan shift to N415 in the N417S
and N417T E2 likely inhibits antibody binding
To determine whether the glycan shift to N415 in
N417S E2 would affect antibody binding, we
determined the crystal structures of hu5B3.v3 and
MRCT10.v362 Fab fragments complexed with the
E2412–423-GSGK-biotin peptide. The peptide configura-
tions conform moderately well to the β-hairpins seen
previously in complexes with the antibodies HCV130
and AP33.31 For instance, most of the H-bonds
within any version of the peptide are shared among
all available structures of the peptide (Table 3). The
close kinship of antibodies MRCT10.v362 and AP33
makes all four versions of the peptide seen in
complexes with them especially similar, with rmsd
values of Cα atoms from residues Ile414–His421
less than 0.15 Å. The analogous calculation using
the HCV1-bound peptide is 0.35 Å. There is a
distinguishing feature of the peptide complexed
with hu5B3.v3; the presence of a type IV hairpin
turn for residues Thr416–Ser419, where all other
peptide structures have the more common type I′
turn. This results in an rmsd for comparison to the
MRCT10.v362 peptide of 0.81 Å. The positions of
the three E2 hydrophobic side chains most intimately417
423
415
(a)
Fig. 3. Attachment of a glycan on E2 residue Asn415 would
andMRCT10.v362. (a) E2 peptide (yellow) directs the Asn415 s
blue; heavy chain in dark blue), where it H-bonds with light-ch
Asn415 side chain toward the Fab MRCT10.v362 surface (light
bonds to heavy-chain Tyr50 (broken line). In both structu
conformation via an H-bond with Gly418, as seen in prior work.
Asn417 and Asn423. The side chains of these residues are dire
and MRCT10 when glycans are attached here.contacting the antibodies, Leu413, Trp420 and
Ile422, cluster in two groups after superposing the
peptides, with those from the complexes with
antibody HCV1 segregated from all others, including
those from hu5B3.v3. The distances between
analogous atoms when compared this way, about
3 Å, is probably no more than one expects for an
exposed β-hairpin loop.
An array of H-bonds and hydrophobic contacts
form the interface between the E2 peptide and
hu5B3.v3 complementarity-determining region
(CDR) loops H1, H2, H3, L1 and L3 (Tables S3
and S5). Since CDR loop L2 is not part of this
paratope, the amino acid changes Gln54 → His and
Gly55 → Ala, which provided enhanced affinity
probably exert this influence via effects on the
neighboring CDRs H1 and L1. An H-bonding
interaction between the Asn415 side chain and
Tyr96 (light chain) and the orientation of the E2
peptide with respect to the antibody are inconsistent
with binding in the presence of glycan attached to
Asn415 (Fig. 3).
All three MRCT10.v362 heavy-chain CDRs and
light-chain CDRs L1 and L3 contact the E2 peptide,
but there is only one residue each from CDRs H1
and H3 that is within 4 Å, Tyr 33 and Tyr100,
respectively (Fig. S3b and Tables S4 and S5). Light-
chain residue Tyr30, introduced during affinity
maturation, has a hydrophobic contact with the
Leu413 side chain, which the original Asn30 in
AP33 does not provide. Ser98 of CDR H3, changed417
423
415
(b)
create an untenable steric clash with antibodies hu5B3.v3
ide chain toward the Fab 5B3.v3 surface (light chain in light
ain Tyr96 (broken line). (b) E2 peptide (yellow) directs the
chain in light green; heavy chain in dark green), where it H-
res, the Asn415 side chain also stabilizes the peptide
Wild-type E2 sequences have glycan attached to residues
cted away from the antibody, consistent with binding of 5B3
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Fig. 4. Enhancement of antiviral effect of NS3 protease
inhibitors by inhibition of HCV entry. DMSO-differentiated
Huh7.5 cells were infected with Jc1 HCVcc (MOI = 0.05)
alone (filled squares) or in the presence of MRCT10.v362
(10 μg/mL, open circles), Telaprevir (2 μM, open triangles)
or a combination of MRCT10.v362 and Telaprevir (open
diamonds). HCV RNA copies were measured at various
times post infection as discussed in Materials and
Methods. HCV cDNA derived from the day 22 post
infection cultures was sequenced (denoted by the aster-
isk). These are representative data from two independent
experiments.
1906 Glycan Shifting in HCV Antibody Resistancefrom threonine during affinity maturation, does not
contact the peptide so its role in binding sE2661
protein is unclear. Similar to the finding for hu5B3.v3,
an H-bond between the Asn415 side chain and
MRCT10.v362 Tyr50 (heavy chain) and the peptide
orientation with respect to the antibody preclude
binding in the presence of a glycan attached at
Asn415 (Fig. 3b).
The structural fidelity with which the humanized
and affinity-matured MRCT10.v362 recapitulates the
paratope of the original murine antibody AP33 is
quite high. There are 13 antibody amino acid
residues within 4.0 Å of the E2 peptide: light-chain
residues Tyr28, Tyr30 (Asn30 in AP33), Phe32,
Asn91, Asn92, Val93, Asp94 and Trp96 and heavy-
chain residues Tyr33, Tyr50, Tyr53, Tyr58 and
Tyr100. The rmsd for the superposition of 13 Cα
pairs is only 0.15 Å. Comparison of Cα atoms for
complete variable domains yields rmsd values of
about 0.5 Å.
The two complexes in the crystallographic asym-
metric unit of the MRCT10.v362/E2 peptide complex
(referred to as ABZ and LHY according to protein
chain identifiers for light chains, heavy chains and
peptide, respectively) are similar overall, but a stark
difference is seen between the two copies of CDR
H1, which have quite different conformations for
residues Gly26–Ser31 in CDR H1 (Figs. S4 and S5).
The rmsd for superposition of the Cα atoms of these
two segments is 1.9 Å. The CDR H1 from ABZ has
intermolecular contacts less than 4 Å for residues
Ser25, Gly26, Asp27 and Ser31, while there are
none for CDR H1 from LHY. Thus, we find that CDR
H1 from LHY adopts the very predominant canonical
“H1-13-1” structure,34 while that seen for ABZ
seems to have been altered by the intermolecular
contacts it experiences. Rather surprisingly, the
conformation of CDR H1 found for AP33 alone and
in complex with the E2 peptide is the unusual one
(“H1-13-2”34), like that of ABZ, and this AP33
conformation arises without intermolecular contacts.
The CDRH1 Tyr33 side chain hydroxyl H-bonds with
the peptide, but Tyr33 is outside the part of this CDR
that differs between the two copies. Thus, this
conformational heterogeneity does not affect antigen
recognition.
Combination of MRCT10with other HCV antivirals
results in enhanced suppression of infection and
spread of resistant virus in vitro
In spite of the rapid emergence of the N417S-
resistant mutant genotype 2a HCVcc in vitro, we
suspected that combination of an entry inhibitor with
an HCV DAA would enhance antiviral efficacy and
perhaps suppress the emergence of resistant
N417S HCVcc. Culturing of Huh7.5 cells in medium
containing 1% dimethyl sulfoxide (DMSO) has been
demonstrated to induce a non-dividing state andcause expression of hepatocyte-specific genes35
and is an appropriate in vitro culture system to study
HCV spread since there is no artificial viral spread
arising from trypsinization. To determine if MRCT10.
v362 could suppress the emergence of resistance to
an approved HCV NS3 protease inhibitor (Telapre-
vir), we infected DMSO-differentiated Huh7.5 cells
with Jc1 HCVcc alone or in the presence of
Telaprevir, MRCT10.v362 or a combination of both
Telaprevir and MRCT10.v362 (Fig. 4). A concentra-
tion of 2 μM Telaprevir was used, which is similar to
the trough concentrations detected in some treated
patients.36 Jc1 HCVcc infection of DMSO-differen-
tiated cells in the presence of Telaprevir induced
early viral suppression but resulted in the emer-
gence of a T54A HCVcc variant ~18 days post
infection (Fig. 4). The T54A mutation has been
demonstrated to confer resistance to Telaprevir and
can be detected in some patients treated with
Telaprevir monotherapy.36,37 Treatment of cells
with 10 μg/mL MRCT10.v362 resulted in no signif-
icant antiviral effect 10 days post infection, consis-
tent with the rapid emergence of the MRCT10.
v362-resistant variants, as detected previously. In
comparison, combination of 10 μg/mL MRCT10.
v362 with Telaprevir resulted in undetectable HCV
RNA replication even at 22 days post infection when
the T54A mutant emerged as the dominant resistant
species in the Telaprevir-treated cultures.Discussion
We have generated two independent affinity-
matured neutralizing antibodies, hu5B3.v3 and
(a) (b) (c)
Fig. 5. The broadly neutralizing anti-HCV antibodies (a) hu5B3.v3 (light chain in light blue; heavy chain in dark blue), (b)
MRCT10.v362 (light chain in light green; heavy chain in dark green) and (c) HCV1 (light chain in light gray; heavy chain in dark
gray) recognize the same surface of the E2412–423 epitope, but each with different details. After superpositioning using VH
domains, the Fab surfaces are shownwith simplified peptide representation (yellow). Peptide side chains for Asn417, a glycan
attachment point in wild-type sequences, and Trp420, central to the epitope, are shown as sticks.
1907Glycan Shifting in HCV Antibody ResistanceMRCT10.v362, that bind to the E2412–423 epitope
and result in significant inhibition of HCVcc entry and
infection in vitro. Using in vitro resistance selections,
we have identified the N417S Jc1 HCVcc variant to
be robustly resistant to all tested neutralizing
antibodies that bind the E2412–423 epitope, including
the HCV1 antibody that is undergoing clinical testing
in humans. Analysis of the glycosylation status of
N415, N417 and N423 has revealed a glycosylation
shift from residue 417 to N415 in the N417S and
N417T mutant E2 glycoproteins, which plays an
important role in the generation of resistance to
broadly neutralizing antibodies. While recent work
has shown that amino acid changes at residue N415
abrogate binding of another E2412–423-specific neu-
tralizing antibody (HCV1),30 our studies show that
changes in adjacent residues can shift glycan
moieties to N415 and thereby produce an analogous
escape from broadly neutralizing HCV antibodies.
Recent studies have proposed a structural basis
for resistance to two broadly neutralizing antibodies,
HCV130 and AP33.29,31 Our structural results from
both an independent neutralizing antibody and a
humanized higher-affinity variant of AP33 are
consistent with their findings. Together, these results
suggest that most, if not all, HCV E2412–423-specific
neutralizing antibodies bind to a similar conformation
of the E2412–423 epitope, a β-hairpin with the
glycosylated asparagines (N417 and N423) pointing
away from the antibody surface. Nonetheless, each
of the three antibodies, MRCT10.v362, hu5B3.v3
and HCV1, bind E2412–423 using distinctly different
antigen recognition surfaces (paratopes), as is made
clear by ~7 Å distances between analogous peptide
Cα atoms when the three structures are superposed
using the VH domains (Fig. 5). In addition, we find
that W420, which has previously been found to be an
essential contact site for binding CD81,38 is buried in
the peptide–antibody interface. Our alanine muta-
genesis studies also revealed that W420 (and L413)
are required for binding of both hu5B3.v3 andMRCT10.v362, consistent with what was recently
shown for HCV1 and AP33.29–31 Since W420 and
N415 are in close proximity and on the same face of
all E2412–423 peptide structures reported to date, this
raises a conceptual conflict regarding functions
assigned to W420 (involved in CD81 binding) and
glycosylated N415 (involved in preventing antibody
binding). Nonetheless, as glycosylation of N415
does not seem to affect CD81 binding since HCV
entry occurs in the N417S mutant, we are left to
speculate that either the CD81–W420 interaction is
relatively indirect or the β-hairpin is not the form of
the E2412–423 peptide during CD81 binding.
Interestingly, while binding of MRCT10.v362 was
only modestly affected by the N415A mutation (3-
fold decreased binding), it completely abrogated
binding by hu5B3.v3 (Fig. 2a). While this effect on
hu5B3.v3 is consistent with the presence in the
hu5B3.v3/E2412–423 complex of an H-bond between
the Asn415 side chain and Tyr96 from the light
chain, the MRCT10.v362/E2412–423 complex in-
cludes an analogous H-bond between Asn415 and
Tyr50 from the heavy chain (Fig. S3). Similarly, there
is a big discrepancy in the effects on antibody affinity
for the G418A mutant peptide—even though the
peptide backbone conformation for Gly418 from the
crystal structures is one that is relatively intolerant of
any other amino acid, the measured effects of
Alanine substitution are ~2-fold (MRCT10.v362)
and ~200-fold (hu5B3.v3). In contrast, while the
HCV1 antibody does not bind the N415A peptide,
there is no H-bonding between N415 and HCV1.30
These data show that the useful concept of a widely
conserved epitope recognized by neutralizing anti-
bodies does not extend to close similarities in
residue-specific contributions of that epitope to
binding energies. Thus, while L413 and W420 are
generally required for tight binding by E2412–423-
specific neutralizing antibodies, different antibodies
may utilize different additional residues. How this
impacts the breadth of neutralization by E2412–423-
1908 Glycan Shifting in HCV Antibody Resistancespecific antibodies and the number of mutations that
could lead to escape is an intriguing question and will
require additional studies.
Glycosylation at N415 in the N417S HCVcc plays
an important role in mediating resistance to
hu5B3.v3 and MRCT10.v362 as there was a
cumulative 82-fold increase in N417S and N417T
mutations as early as 5 days post treatment with
AP33 identified by ultra deep sequencing. This is
particularly interesting since both N417S and N417T
mutations result in a shift of the glycan from residue
417 to N415, suggesting that the presence of a
glycan at N415 is preferred during early antibody
pressure. Based on our structural results, it is
straightforward to predict that the glycan shift to
N415 will result in resistance to hu5B3.v3 and
MRCT10.v362 and probably most if not all other
E2412–423-specific neutralizing antibodies. While the
N417 side chain is pointing away from both
hu5B3.v3 and MRCT10.v362 Fab faces, the N415
side chain is buried in the peptide–antibody interface
and involved in H-bonds with antibody side chains.
The presence of even a single glycan residue at this
position is quite inconsistent with all the interactions
seen between peptide and the Fabs—there is simply
no room. N417 is a bona fide N-linked glycosylation
site and HCVpp containing an N417Q mutation in
E2, which results in the loss of glycosylation at that
site, was demonstrated to be ~50% more sensitive
to neutralization by AP33 compared to the wild-type
HCVpp. This led the authors to propose that the
N417 glycan may be masking the E2412–423 epitope
from broadly neutralizing antibodies.26,39 Our data
suggest that this may not apply to all E2412–423-
specific neutralizing antibodies since the N417G
Jc1 HCVcc mutant, which like the N417Q virus is
not glycosylated at either residue 415 or residue
417, is no more sensitive to neutralization by AP33
and MRCT10.v362. In fact, N417G Jc1 HCVcc is
11-fold and 18-fold more resistant to two other
E2412–423-specific antibodies, hu5B3.v3 and HCV1,
respectively (Table 2). These data suggest that, at
least in genotype 2a HCV, the N417 glycan may
not be as important for evasion against E2412–423-
specific antibodies and that specific mutations at
N417 may play different roles in determining the
affect on neutralization by E2412–423-specific
antibodies.
The role of glycosylation in regulating resistance to
neutralizing antibodies has been extensively studied
for human immunodeficiency virus 1.40–44 In partic-
ular, human immunodeficiency virus 1 escape from
neutralizing antibodies also involves changes in N-
linked glycosylation that conferred escape from
autologous patient antibodies and epitope-specific
monoclonal antibodies.40 Our data suggest that
multiple viruses, including HCV, may have evolved
mechanisms to shift their glycan shield in order to
escape from potent neutralizing antibodies. Whilethe N417S-resistant virus can be detected in
genotype 1 HCV-infected chimpanzees45 and HCV
isolates containing mutations at N415 and N417
were also detected in HCV-infected patients under-
going liver transplants who were administered the
HCV1 antibody,46 we are encouraged to learn that,
in spite of the robust in vitro resistance of the N417S
mutant virus to E2412–423-specific neutralizing anti-
bodies, the combination with other HCV antivirals
not only resulted in synergistic antiviral efficacy but
also suppressed the emergence of resistance to
both the HCV protease inhibitor Telaprevir and
MRCT10.v362. These data demonstrate that entry
inhibition may also serve as a novel salvage antiviral
mechanism in patients who do not respond well to
other HCV DAAs and inform the development of
novel HCV vaccine antigens that would allow for the
development of a broadly reactive neutralizing
antibody response.Materials and Methods
Development and characterization of mouse
anti-HCV E2 antibody 5B3 (mu5B3)
Balb/c mice (Charles River, Hollister, CA) were primed
with 10 μg pORF-mFlt3L plasmid DNA, followed with
weekly immunizations of 50 μg plasmid DNA encoding
HCV E1–E2 and 2.5 μg mGM-CSF plasmid DNA (Gen-
entech) diluted in lactated Ringer's solution via hydrody-
namic tail vein injection as previously described.47–49
Serum was screened for neutralizing activity against
genotypes 1a and 1b HCVpp. Three days following the
last hydrodynamic tail vein immunization, splenocytes
were taken from the mouse that showed strongest
neutralization activity and fused with X63-Ag8.653
mouse myeloma cells (American Type Culture Collection,
Rockville, MD) via electrofusion (Cytopulse, Glen Burnie,
MD), then incubated at 37 °C, 7% CO2, overnight in
Dulbecco's modified Eagle's medium (DMEM; Lonza,
Basel, Switzerland) supplemented with 10% fetal bovine
serum, 4.5 g/L glucose, 25 mM Hepes, 0.15 mg/mL
oxaloacetic acid, 100 μg/mL pyruvic acid, 0.2 U/mL
insulin, 2 mM L-glutamine, 100 U/mL penicillin and
100 μg/mL streptomycin (Invitrogen, Carlsbad, CA),
NCTC-109 (Lonza, Allendale, NJ) and NEAA (Invitrogen),
before plating into 96-well plates supplemented with
5.7 μM azaserine and 100 μM hypoxanthine (Sigma-
Aldrich, St. Louis, MO). Supernatants were screened for
IgG production by ELISA 11 days post-fusion and tested
for binding to 293 cells transiently transfected with HCV
E1E2-expressing plasmids by fluorescence-activated cell
sorter. Hybridomas demonstrating strong HCV glycopro-
tein-specific binding by fluorescence-activated cell sorter
were screened for neutralizing activity against GT1a,
GT1b and GT2a HCVpp. One neutralizing antibody
clone, 5B3, was expanded and subcloned by two rounds
of limiting dilution, then expanded for large-scale produc-
tion in bioreactors (Integra Biosciences, Chur, Switzer-
land). Supernatant was then purified by protein A affinity
chromatography as previously described.49
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The HCV amino acid positions are numbered according
to the genotype 1a H77 polyprotein sequence. Sequence
changes resulting in apparent improved affinity were
transferred into mammalian IgG expression vectors,
transiently expressed in CHO (Chinese hamster ovary)
cells and purified by affinity chromatography on protein A
Sepharose. SPR measurements of sE2661 binding to
antibody were performed on a Biacore 4000 instrument
(GE Healthcare, Pittsburgh, PA) using the human antibody
capture kit as described by the manufacturer. Sensor-
grams were recorded for injections of 60 μL at 30 μL/min
of solutions of sE2661 ranging in concentration from 1.5 nM
to 100 nM in 2-fold increments. Kinetic constants were
determined using 4000 Evaluation Software v1.0. Fab
fragments were prepared by LysC endoprotease cleavage
of intact IgG as previously demonstrated.50 Dissociation
constants (KD) for Fab binding to peptide epitope
QLINTNGSWHIN attached to biotin via a GSGK linker
(E2412–423-GSGK-biotin) were determined by bio-layer inter-
ferometry on a ForteBio Octet Red384. Briefly, streptavidin
biosensor tips were incubated with 5 μg/mL biotinylated
peptide followed by 100 nM Fab. Binding constants were
calculated from the response profile using Data Analysis
Software v6.4.
To detect antibody binding to HCV E1E2-expressing
293T cells by ELISA, we coated 96-well Immulon™ 2 HB
plates (Immunochemistry Technologies, Bloomington,
MN) with 0.25 μg/well GNA (Galanthus nivalis lectin)
overnight at room temperature. Plates were washed 6×
with phosphate-buffered saline (PBS) containing 0.02%
Tween 20. GNA-coated plates were then incubated with
lysates of 293T cells transfected with plasmids encoding
HCV E1–E2 from genotypes 1a (H77), 1b (Con1) and 2a
(J6) for 2 h at room temperature. Plates were washed 6×
with PBS containing 0.02% Tween 20 followed by
incubation with 5 mg/mL of AP33, MRCT10.v362,
mu5B3, hu5B3.v3 and HCV1 antibodies for 2 h at room
temperature. Binding was detected using anti-human and
anti-mouse horseradish-peroxidase-conjugated anti-
bodies and TMB substrate (Rockland Immunochemicals,
Gilbertsville, PA). The reaction was stopped by adding 1 M
phosphoric acid and an OD450 was measured using a
Synergy 2 Microplate Reader (Biotek, Winooski, VT).Tissue culture and generation of full-length infectious
HCVcc cDNA
Huh7.5 cells were obtained from Apath LLC under
license and cultured in complete DMEM (supplemented
with 10% fetal calf serum, 100 U/mL penicillin, 100 mg/mL
streptomycin, 2 mM L-glutamine and 0.1 mM non-essen-
tial amino acids).51–53 The J6/C3 (Jc1; genotype 2a) and
bicistronic Con1/C3 (genotype 1b) chimeric genomes were
generated as previously described.54Generation of infectious HCVcc and HCVpp stocks
Jc1 and Con1/C3-neo HCVcc virus stocks were
generated by transfecting Huh7.5 cells with in vitro
transcribed full-length HCV RNA as described pre-
viously.53,54 Plasmids were linearized with XbaI and invitro transcribed RNA was generated using Megascript Kit
(Life Technologies, Grand Island, NY) as per manufac-
turer's instructions. HCV RNA was transfected into Huh7.5
cells by electroporation as described previously.53,54
Supernatants from Jc1 RNA-transfected cells were har-
vested starting from 3 days post transfection, titered and
pooled to generate laboratory stocks. HCVcc titers were
measured using the TCID50 calculator as described
previously.55 HCVpp stocks were generated as previously
described.54
Antibodies used in HCV neutralization assays
Genes for the HCV1 antibody heavy- and light-chain
variable domains were synthesized (Blue Heron Inc.,
Bothell, WA) on the basis of the published amino acid
sequence (Ref. 17; patent application PCT/US2008/
001922). Sequences were codon optimized for expression
in mammalian cells. The variable heavy domain was cloned
on an EcoRI/ApaI fragment into a human IgG1 expression
plasmid.56 Similarly, the variable light domain was cloned
on an EcoRI/BlpI fragment into a human kappa light-chain
expression plasmid. HCV1 protein was transiently pro-
duced by co-transfection of CHO cells with an equimolar
mixture of heavy- and light-chain expression plasmids and
antibody was purified by affinity chromatography on protein
A Sepharose. Anti-CD81 clone JS-81 (BD Pharmingen,
San Diego, CA) and anti-CLDN1 clone 5.16v554 were used
as controls for HCV neutralization assays.
Neutralization assays
Multiplicity of infection (MOI) for Jc1 HCVcc was
calculated based on virus titer as measured by TCID50
calculations.55 HCVpp stocks were normalized for lucifer-
ase activity before infecting cells. Neutralization assays
using HCVpp or HCVcc viruses were performed as
described previously.54,57
RNA extractions, reverse transcription and real-time
quantitative PCR analysis
Real-time quantitative PCR analysis was performed as
described previously.51,54,57 Data were analyzed using
relative expression (2−ΔΔCT method) normalized to
GAPDH as described previously.52,58
Ultra deep sequencing of in vitro resistance selection
and chronic patient sera
Total RNA was extracted from ~5 × 104 cells per
sample (per 24 wells) using RNeasy Mini spin columns.
HCV E1E2 cDNA was generated using One-Step RT-PCR
kit (Qiagen) according to the manufacturer's instructions
using the following primers: (sense) 5′-GGAGGACGG-
GGTTAATTTTG-3′ and (antisense) 5′-CCCGACCCTT-
GATGTACCAA-3′. The E1E2 cDNAs were used as
templates to generate ~200-bp PCR products covering
the E2412–423 epitope using primers tagged with 454
barcodes as listed in Table S1. All PCR products were
gel-purified before 454 sequencing (454 Life Sciences,
Branford, CT).
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house computer programs. Briefly, a data-processing
pipeline was established to handle sequence read files
and the quality score files simultaneously and to detect
barcode errors. Readswere binned using 5′ and 3′ barcodes
and translated in the appropriate frame. Sequence reads
with b100 nucleotides were filtered out, together with
translated sequences that did not contain a predefined
amino acid motif adjacent to the region of interest. The
pipeline was used to generate amino acid frequencies for
code pairs, consensus sequences and amino acid frequen-
cies at specific positions for each code pair.Protein purification and mass spectrometric analysis
We seeded 5 × 106 Huh7.5 cells in T225 flasks, and the
following day, we transfected the cells with a plasmid
expressing soluble genotype 2a J6CF sE2661 containing
either wild-type (N417) or mutant residues (N417G,
N417S, N417T) using Lipofectamine 2000, according to
the manufacturer's instructions. After incubation with the
Lipofectamine–DNA mix for 5 h, media was replaced with
DMEM supplemented with fetal bovine serum (2% final
concentration). After 72 h, supernatant was collected and
clarified using a 0.2 μM filter. Fifty milliliters of the
transfected Huh7.5 conditioned media was batched at
4 °C with Ni-NTA resin and then processed in column
format. The column was washed with PBS, 1 mM azide
(Buffer A) down to baseline, followed by 25 mM imidazole
with 0.3 M sodium chloride in Buffer A to baseline then
elutedwith 250 mM imidazole and 0.3 Msodium chloride in
Buffer A. Five micrograms of the eluted protein was
reduced with 10 mM dithiothreitol and alkylated with
15 mM N-isopropyl-2-iodoacetamide. The alkylation reac-
tion was stopped with 250 mM β-mercaptoethanol, and the
sample was added to SDS sample buffer, separated on a
SDS gel then transblotted to a polyvinylidene fluoride
membrane.
HCV electroblotted sample bands were excised,
blocked with 0.5% Zwittergent 3–16 (Calbiochem, Biller-
ica, MA) and deglycosylated with PNGase F (New England
Biolabs) in 50 mM Tris–HCl (pH 8.0) for 2 h at 45 °C. The
deglycosylated samples were then digested with 0.2 μg
trypsin (Promega, Madison, WI) in 10% acetonitrile/
100 mM Tris (pH 8.0) for 1 h at 37 °C. Equivalent samples
treated with non-PNGase F were processed in parallel.
The digested samples were analyzed by capillary reverse
phase ultra-performance liquid chromatography (UPLC)
electrospray ionization MS/MS on an LTQ-Orbitrap XL
mass spectrometer (ThermoElectron, Madison, WI). Sam-
ples were loaded in 0.1% trifluoroacetic acid in water onto
a 100-μm i.d. capillary column (nanoAcquity UPLC
column, 100 μm × 100 nm, 1.7 μm, BEH130 C18; Waters
Corp). Peptides were eluted with a 45-min gradient of 5–
90% Buffer B (where Buffer A was composed of 0.1%
formic acid in water and Buffer B was composed of 0.1%
formic acid in acetonitrile) at 1.00 μL/min generated by a
UPLC system (nanoAcquity UPLC; Waters Corp). Mass
spectral data were acquired using methods that included
one full MS scan (400–1600 m/z) in the Orbitrap at
resolution of 60,000 M/ΔM at m/z 400 followed by
collision-induced dissociation of the top 5 most abundant
ions detected in the full MS scan and several targeted
product ion scans in the ion trap. Ions chosen for targetedexperiments included the doubly charged HCV tryptic
peptides containing N415, N417 and N423 in their
potential non-deamidated and deamidated states. The
tandemmass spectral results were submitted for database
searching using the Mascot program (Matrix Science)
against an in-house curated protein database and the
Swiss-Prot database. The following search parameters
were specified: full trypticity, one miscleavage, variable
modifications on Asn/Gln deamidation (+0.984 Da), Met
oxidation (+15.995 Da), Cys N-isopropyl carboxamido-
methylation (+99.068 Da), 20 ppm precursor ion mass
and 0.5 Da fragment ion mass tolerance. Deamidated
peptide identifications were confirmed by manual interpre-
tation of mass spectral data.Antibody/antigen complex preparation
Fab fragments of hu5B3.v3 and MRCT10.v362 were
diluted using 0.6% acetic acid and each was loaded onto a
5-mL S-Sepharose fast flow cation-exchange column and
eluted with a 10 CV linear gradient from 25 mM 4-
morpholineethanesulfonic acid (Mes) (pH 5.5) to 0.5 M
NaCl and 25 mM Mes (pH 5.5). The peak fractions were
pooled and concentrated to 20 mg/mL. A 2-fold molar
excess of E2412–423-GSGK-biotin was added to each of the
Fab fragments and incubated for 12 h at 4 °C. The protein
complexes were screened for crystallization in sitting
drops using the Phoenix robot (Art Robbins) and commer-
cial screening solutions. Crystallization droplets consisted
of 0.2 μL protein and 0.2 μL reservoir at 18 and 4 °C. The
5B3.v3/E2 complex crystallized after 2 days with 0.1 M
Mes (pH 6.0) and 2.4 M ammonium sulfate at 18 °C. A
cryoprotectant consisting of glycerol 25% (v/v) final
concentration added to the reservoir permitted preserva-
tion by immersion in liquid nitrogen. The MRCT10.v362/E2
complex crystallized after several months in 0.1 M LiCl,
20% (w/v) polyethylene glycol 6000 and 0.1 M Tris
(pH 8.5) at 18 °C. Polyethylene glycol 3350 25% (w/v)
final was added to the reservoir and harvested crystals
were preserved by immersion in liquid nitrogen.Hu5B3.v3 Fab/E2412–423-GSGK-biotin structure
determination
Data in a tetragonal point group extending to 2.6 Å
resolution were collected at Stanford Synchrotron Radia-
tion Lightsource beamline 11–1. Data reduction
(HKL200059) and structure solution by molecular replace-
ment (Phaser60) allowed assignment of the space group
as P41212. The molecular replacement search probes
were separate constant region and Fv fragments searched
stepwise, and the Fv fragment lacked CDR loop regions.
After care was taken to identify CDR loops in the initial
electron density maps, a tentative polyalanine peptide was
built (Coot61). After refinement of this model, electron
density suggestive of the peptide side chains permitted
confident assignment of the peptide direction and se-
quence. Refinement was performed using Phenix62 and
Refmac563 and included TLS treatment of thermal factors.
The E2-derived peptide is resolved from Gln412 to
Asn423, leaving the linker residues 424–427 (Gly-Ser-
Gly-Lys) and the C-terminal biotin unresolved. A flat Fo −
Fc map in the E2 peptide region was obtained using main-
Table 4. Data collection and refinement for Fab/E2412–423-GSGK-biotin complexes
FabMRCT10.v362/pep Fab5B3.v3/pep
Data collection CLS 08ID-1 SSRL 11-1
Space group P21 P41212
Unit cell parameters
a, b, c (Å) 71.09, 90.82, 72.68 77.72, 77.72, 181.4
α, β, γ (°) 90, 109.3, 90 90, 90, 90
VM (Å
3/Da) 2.3 2.9
Resolution (Å) 50–1.53 50–2.60
Rsym
a,b 0.052 (0.552) 0.098 (0.713)
Number of observations 487,066 137,676
Unique reflections 131,070 17,880
Completeness (%)b 99.9 (99.2) 99.9 (100)
I/σIb 23.0 (2.2) 19.2 (3.2)
Wilson B (Å2) 21 72
Refinement
Resolution (Å) 50–1.53 50–2.60
Refs. [F N 0(σF)] 129,605 17,838
Final Rcryst,
c Rfree 0.175, 0.200 0.222, 0.264
Molecules per asymmetric unit 2 1
Protein residues 889 455
Solvent molecules 1059 36
Atoms 7968 3540
Non-crystallographic symmetry rmsd
(light chain, heavy chain, peptide) (Å)
0.73, 0.81, 0.49 Not applicable
Mean B-factor (light chain/heavy chain/peptide/water/all) (Å2) 25/21/26/28/24
25/22/27/—/—
62/67/78/53/65
rmsd bonds (Å) 0.008 0.009
rmsd angles (°) 1.2 1.3
Number of TLS groups 23 5
Ramachandran (%) 96/3/1 95/4/1
a Rsym = ∑||I| − |〈I〉||/∑|〈I〉|, where I is the intensity of a single observation and 〈I〉 is the average intensity for symmetry-equivalent
observations.
b Values in parentheses are for the highest-resolution shell.
c Rcryst = ∑|Fo − Fc|/∑|Fo|, where Fo and Fc are observed and calculated structure factor amplitudes, respectively. Rfree is calculated as
R for reflections sequestered from refinement.
1911Glycan Shifting in HCV Antibody Resistancechain torsion angles for residues 417 and 418 best
described as type IV turn, which produces a close contact
for H-atoms on the adjacent amide nitrogen atoms of T416
and N417. Reference to the higher-resolution MRCT0.
v362/ E2412–427-GSGK-biotin structure permitted a refinement
experiment that relieved this apparent clash but that
resulted in relatively large Fo − Fc features, which could
be accounted for by the original model that was therefore
retained (Fig. S6). Data reduction and final refinement
statistics appear in Table 4.
MRCT10.v362 Fab/E2412–423-GSGK-biotin structure
determination
Data in the monoclinic point group extending to 1.53 Å
resolution were collected at Canadian Light Source
beamline 08ID-1 by Shamrock Structures, LLC (Wood-
ridge, IL). Data reduction and structure solution (in space
group P21) were performed as above, except that the
asymmetric unit contains two complexes. After building all
CDR loops, extra electron density was assigned to the E2
peptide. Optimal fit of the peptide from the Fab5B3
complex required adjustment of the peptide residues
415–417. Non-crystallographic symmetry restraints were
applied between all three pairs of homologous poly-peptides, and TLS treatment of thermal factors was
used. Data reduction and final refinement statistics appear
in Table 4.Jc1 HCVcc infection of DMSO-differentiated Huh7.5 cells
Huh7.5 cells (90% confluent) were cultured in collagen-
coated, 96-well plates in the presence of complete DMEM
containing 1% DMSO. Culture media was replenished
every 2 days for 14 days after which cells were infected
with Jc1 HCVcc (MOI = 0.05). One day post infection, cells
were treated with either 10 μg/mL MRCT10-v362 or 2 μM
Telaprevir alone or in combination. Fresh inhibitors were
added every 2 days until day 22 post infection. HCV RNA
replication was measured at various times post infection
by real-time quantitative PCR as described above.Statistical analyses
All statistical analyses were performed using GraphPad
Prism software (GraphPad, San Diego, CA). All graphs
represent the mean ± standard error of the mean (SEM)
unless stated otherwise. p values for all data were
determined using the regular t test unless otherwise
1912 Glycan Shifting in HCV Antibody Resistanceindicated (p values: *p b 0.05, **p b 0.01 and ***p b 0.001
are denoted when appropriate).
Accession numbers
Final coordinates and structure factors from MRCT10.
v362 and hu5B3.v3 Fabs complexed with E2 peptide have
been deposited in the Protein Data Bank under accession
codes 4HS6 and 4HS8, respectively.Acknowledgements
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